ATE381542T1 - Nr1h4-kern-rezeptor-bindende verbindungen - Google Patents
Nr1h4-kern-rezeptor-bindende verbindungenInfo
- Publication number
- ATE381542T1 ATE381542T1 AT01119473T AT01119473T ATE381542T1 AT E381542 T1 ATE381542 T1 AT E381542T1 AT 01119473 T AT01119473 T AT 01119473T AT 01119473 T AT01119473 T AT 01119473T AT E381542 T1 ATE381542 T1 AT E381542T1
- Authority
- AT
- Austria
- Prior art keywords
- nr1h4
- receptor binding
- binding compounds
- compounds
- core receptor
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 102100038495 Bile acid receptor Human genes 0.000 title abstract 3
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 title abstract 3
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000006255 nuclear receptors Human genes 0.000 abstract 1
- 108020004017 nuclear receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/11—Compounds covalently bound to a solid support
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01119473A EP1285914B1 (de) | 2001-08-13 | 2001-08-13 | Nr1h4-kern-rezeptor-bindende verbindungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE381542T1 true ATE381542T1 (de) | 2008-01-15 |
Family
ID=8178316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01119473T ATE381542T1 (de) | 2001-08-13 | 2001-08-13 | Nr1h4-kern-rezeptor-bindende verbindungen |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US7034046B2 (de) |
| EP (3) | EP1285914B1 (de) |
| AT (1) | ATE381542T1 (de) |
| DE (1) | DE60131967D1 (de) |
| WO (2) | WO2003015771A1 (de) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1392714B1 (de) | 2001-03-12 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Steroide als agonisten für fxr |
| US6987121B2 (en) | 2002-04-25 | 2006-01-17 | Smithkline Beecham Corporation | Compositions and methods for hepatoprotection and treatment of cholestasis |
| WO2003099793A1 (en) * | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
| EP1562915A1 (de) | 2002-11-22 | 2005-08-17 | SmithKline Beecham Corporation | Farnesoid x rezeptor agonisten |
| JP2007524651A (ja) * | 2003-09-26 | 2007-08-30 | フォーブス メディ−テック インコーポレーテッド | 多剤耐性遺伝子の発現を抑制して、該遺伝子の発現によって生じるタンパク質の製造を抑制し、それにより、癌治療のための化学療法薬の有効性を高める方法。 |
| WO2005042692A2 (en) * | 2003-10-31 | 2005-05-12 | Forbes Medi-Tech Inc. | A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors |
| US7829552B2 (en) | 2003-11-19 | 2010-11-09 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyromimetics |
| BRPI0418082B8 (pt) * | 2003-12-26 | 2021-05-25 | Kyowa Hakko Kirin Co Ltd | derivados de tiazol úteis como antagonistas de receptor de adenosina a2a |
| US10987362B2 (en) | 2004-03-12 | 2021-04-27 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using FXR ligands |
| US9498484B2 (en) | 2004-03-12 | 2016-11-22 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using FXR ligands |
| WO2006017211A1 (en) * | 2004-07-12 | 2006-02-16 | Research Development Foundation | Guggulsterone as an inhibitor of nuclear factor-kb and ikbalpha kinase activation |
| EP1773768B8 (de) * | 2004-07-30 | 2018-12-26 | Exelixis, Inc. | Pyrrolderivate als pharmazeutische wirkstoffe |
| WO2006029719A2 (en) * | 2004-09-14 | 2006-03-23 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with nuclear receptor subfamily 1, group h, member 4 (nr1h4) |
| US20060252670A1 (en) * | 2004-10-14 | 2006-11-09 | Intercept Pharmaceuticals Inc. | Method of reducing drug-induced adverse side effects in a patient |
| ITMI20050912A1 (it) * | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| JP2008542301A (ja) | 2005-05-26 | 2008-11-27 | メタバシス・セラピューティクス・インコーポレイテッド | 脂肪性肝疾患の処置のための甲状腺ホルモン様薬剤 |
| US7618956B2 (en) * | 2005-05-31 | 2009-11-17 | The Gillette Company | Reduction of hair growth |
| WO2007052843A1 (ja) * | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
| ES2374165T3 (es) | 2005-12-19 | 2012-02-14 | Glaxosmithkline Llc | Agonistas del receptor x farnesoide. |
| BRPI0707427A2 (pt) * | 2006-02-03 | 2011-05-03 | Lilly Co Eli | composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar dislipidemia, aterosclerose, e diabetes e complicações da mesma, para elevar os nìveis plásmicos de hdl, e para diminuir triglicerìdeos plásmicos, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo |
| EA015632B9 (ru) | 2006-05-24 | 2012-08-30 | Эли Лилли Энд Компани | Агонисты fxr |
| DE602007005256D1 (de) * | 2006-05-24 | 2010-04-22 | Lilly Co Eli | Verbindungen und verfahren zur modulierung von fx-rezeptoren |
| EP1886685A1 (de) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methoden, Verwendungen und Zusammensetzungen zur Modulation der Replikation von HCV durch Aktivierung oder Hemmung des Farnesoid X Rezeptors |
| EP1894928A1 (de) * | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Fxr bindende heterocyclische verbindungen |
| EP1894924A1 (de) * | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterozyklische FXR Bindungsverbindungen |
| CL2007003035A1 (es) | 2006-10-24 | 2008-05-16 | Smithkline Beechman Corp | Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos, |
| WO2008091540A2 (en) | 2007-01-19 | 2008-07-31 | Intercept Pharmaceuticals, Inc. | 23-substituted bile acids as tgr5 modulators and methods of use thereof |
| CA2690406A1 (en) * | 2007-07-02 | 2009-01-08 | Glaxosmithkline Llc | Farnesoid x receptor agonists |
| TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| MX2010005753A (es) | 2007-12-04 | 2010-06-15 | Hoffmann La Roche | Derivados de isoxazolo-pirazina. |
| US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| US7902201B2 (en) | 2007-12-04 | 2011-03-08 | Hoffmann-La Roche Inc. | Isoxazolo-pyrazine derivatives |
| EP2128158A1 (de) | 2008-05-26 | 2009-12-02 | Phenex Pharmaceuticals AG | Heterocyclische Cyclopropyl-substituierte FXR-bindende Verbindungen |
| AU2009276507B2 (en) * | 2008-07-30 | 2015-11-19 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
| JP2012506386A (ja) * | 2008-10-21 | 2012-03-15 | メタボレックス， インコーポレイテッド | アリールｇｐｒ１２０受容体アゴニストおよびその使用 |
| SG10201400162QA (en) | 2008-11-19 | 2014-05-29 | Intercept Pharmaceuticals Inc | Tgr5 modulators and methods of use thereof |
| US20110257139A1 (en) | 2008-12-19 | 2011-10-20 | Royal College Of Surgeons In Ireland | Treatment of diarrhoea |
| TW201033201A (en) | 2009-02-19 | 2010-09-16 | Hoffmann La Roche | Isoxazole-isoxazole and isoxazole-isothiazole derivatives |
| US8389550B2 (en) | 2009-02-25 | 2013-03-05 | Hoffmann-La Roche Inc. | Isoxazoles / O-pyridines with ethyl and ethenyl linker |
| US8222246B2 (en) | 2009-04-02 | 2012-07-17 | Hoffmann-La Roche Inc. | Substituted isoxazoles |
| US20100280019A1 (en) | 2009-04-30 | 2010-11-04 | Roland Jakob-Roetne | Isoxazoles |
| EP2427455B1 (de) | 2009-05-05 | 2020-01-15 | F.Hoffmann-La Roche Ag | Isoxazol-pyrazole derivate |
| AU2010244545A1 (en) | 2009-05-05 | 2011-10-13 | F. Hoffmann-La Roche Ag | Isoxazole-pyridazine derivatives |
| BRPI1011729A2 (pt) | 2009-05-05 | 2016-03-15 | Hoffmann La Roche | derivados de isoxazol-tiazol como um receptor inverso gaba a agonista para uso no tratamento de distúrbios cognitivos |
| SG175867A1 (en) | 2009-05-05 | 2011-12-29 | Hoffmann La Roche | Isoxazole-pyridine derivatives |
| AU2010244555A1 (en) | 2009-05-07 | 2011-11-03 | F. Hoffmann-La Roche Ag | Isoxazole-pyridine derivatives as GABA modulators |
| EP2289883A1 (de) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Neue Aktivitätsmodulationsverbindungen für FXR- (NR1H4) |
| EP2545964A1 (de) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Neuartige FXR- (NR1H4)-Binde- und -Aktivitätsmodulationsverbindungen |
| WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
| US8785435B2 (en) | 2011-10-20 | 2014-07-22 | Hoffmann-La Roche Inc. | Solid forms |
| SG10201607230SA (en) | 2012-06-19 | 2016-10-28 | Intercept Pharmaceuticals Inc | Preparation, Uses And Solid Forms Of Obeticholic Acid |
| US9982008B2 (en) | 2012-06-19 | 2018-05-29 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
| JP6366721B2 (ja) | 2013-09-11 | 2018-08-01 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｂ型肝炎ウイルス感染症を処置するための方法及び医薬組成物 |
| EP3006939A1 (de) | 2014-10-06 | 2016-04-13 | Gilead Sciences, Inc. | Histidinreiches Glycoprotein als Marker zur hepatischen Farnesoid-X-Aktivierung |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| EP3034499A1 (de) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Neuartige FXR (NR1H4) modulierende Verbindungen |
| EP3034501A1 (de) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxyhaltige FXR (NR1H4) modulierende Verbindungen |
| AR103624A1 (es) | 2015-02-06 | 2017-05-24 | Intercept Pharmaceuticals Inc | Composiciones farmacéuticas para terapia de combinación |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| SI3277286T1 (sl) | 2015-03-31 | 2021-09-30 | Enanta Pharmaceuticals, Inc. | Derivati žolčne kisline kot antagonisti FXR/TGR5 in metode za njihovo uporabo |
| CA2981507A1 (en) | 2015-04-07 | 2016-10-13 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions for combination therapy |
| WO2017189652A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US10138228B2 (en) | 2016-05-18 | 2018-11-27 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use therof |
| US10144729B2 (en) | 2016-05-18 | 2018-12-04 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| US10149835B2 (en) | 2016-05-18 | 2018-12-11 | Elmore Patent Law Group, P.C. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| ES2921432T3 (es) | 2016-06-13 | 2022-08-25 | Gilead Sciences Inc | Derivados de azetidina como moduladores de FXR (NR1H4) |
| TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| EP3523298A4 (de) | 2016-10-04 | 2020-06-24 | Enanta Pharmaceuticals, Inc. | Isoxazolanaloga als fxr-agonisten und verfahren zur verwendung davon |
| US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
| EP3541395A4 (de) | 2016-11-21 | 2020-07-01 | Viking Therapeutics, Inc. | Verfahren zur behandlung einer glykogenspeicherkrankheit |
| EP4424364B1 (de) | 2017-03-28 | 2026-01-21 | Gilead Sciences, Inc. | Kombinationen zur verwendung bei der behandlung von zirrhose und leberfibrose |
| EP3600293A1 (de) | 2017-03-30 | 2020-02-05 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Verfahren und pharmazeutische zusammensetzungen zur reduzierung und expression von episomalen viren |
| SI3612520T1 (sl) | 2017-04-12 | 2022-01-31 | Il Dong Pharmaceutical Co., Ltd. | Izoksazolni derivati kot agonisti nuklearnega receptorja in njihove uporabe |
| EP3634426A4 (de) | 2017-06-05 | 2021-04-07 | Viking Therapeutics, Inc. | Zusammensetzungen zur behandlung von fibrose |
| KR102731925B1 (ko) | 2017-11-01 | 2024-11-18 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 멀티시클릭 화합물 |
| CN111630051B (zh) | 2017-11-01 | 2023-12-26 | 百时美施贵宝公司 | 作为法尼醇x受体调节剂的烯烃螺环化合物 |
| KR102732404B1 (ko) | 2017-11-01 | 2024-11-19 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 알켄 화합물 |
| US10689391B2 (en) | 2017-12-12 | 2020-06-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| CA3094167A1 (en) | 2018-03-22 | 2019-09-26 | Viking Therapeutics, Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
| IT201800007265A1 (it) * | 2018-07-17 | 2020-01-17 | Isossazoli come agonisti del recettore fxr | |
| WO2020117962A1 (en) | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| PE20211907A1 (es) | 2019-01-15 | 2021-09-28 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4) |
| KR102725082B1 (ko) | 2019-02-19 | 2024-11-04 | 길리애드 사이언시즈, 인코포레이티드 | Fxr 효능제의 고체 형태 |
| US11555032B2 (en) | 2019-05-13 | 2023-01-17 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| EA202193334A1 (ru) | 2019-05-30 | 2022-03-14 | Интерсепт Фармасьютикалз, Инк. | Фармацевтические композиции, содержащие агонист fxr и фибрат, для применения при лечении холестатического заболевания печени |
| AU2020312735A1 (en) | 2019-07-18 | 2021-12-16 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| CN112824394B (zh) * | 2019-11-21 | 2024-08-13 | 中国科学院上海药物研究所 | PPARs-FXR多靶点小分子激动剂及其制备方法和用途 |
| WO2021108974A1 (en) | 2019-12-03 | 2021-06-10 | Gannex Pharma Co., Ltd | Compounds for modulating activity of fxr and uses thereof |
| US20230060715A1 (en) | 2020-01-15 | 2023-03-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fxr agonists for treating an infection by hepatitis d virus |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| US20240100125A1 (en) | 2021-01-14 | 2024-03-28 | Enyo Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
| JP2024517181A (ja) | 2021-04-28 | 2024-04-19 | ウエヌイグレックオ・ファーマ | 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2863874A (en) * | 1955-05-26 | 1958-12-09 | Goodrich Co B F | Process of preparing 2-aminothiazoles |
| AU545463B2 (en) * | 1982-06-25 | 1985-07-18 | Kowa Co. Ltd. | Benzoyl piperacine esters |
| JPS59139357A (ja) * | 1983-01-28 | 1984-08-10 | Torii Yakuhin Kk | アミジン誘導体 |
| DE3621372A1 (de) * | 1986-06-26 | 1988-01-07 | Thomae Gmbh Dr K | Heterocyclisch substituierte 3,5-dihydroxy-hept-6-en-carbonsaeuren, ihre derivate, verfahren zur herstellung dieser verbindungen und die sie enthaltende arzneimittel |
| DE4237768A1 (en) * | 1991-11-12 | 1993-05-13 | Ciba Geigy Ag | New polyarylene ether derivs. with reduced viscosity - used to prepare moulded bodies, foils, fibres and membranes, as matrix resins, adhesives or coating agents or as polymer additives |
| DE4219247A1 (de) * | 1992-06-12 | 1993-12-16 | Bayer Ag | Verwendung von 3-arylsubstituierten 5-Alkyl-isoxazol-4-carbonsäurederivaten zur Bekämpfung von Endoparasiten, neue 3-arylsubstituierte 5-Alkyl-isoxazol-4-carbonsäurederivate und Verfahren zu ihrer Herstellung |
| FR2692893B1 (fr) | 1992-06-24 | 1994-09-02 | Sanofi Elf | Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. |
| US6005103A (en) * | 1993-11-19 | 1999-12-21 | Warner-Lambert Company | Pyrone derivatives as protease inhibitors and antiviral agents |
| FR2714059B1 (fr) | 1993-12-21 | 1996-03-08 | Sanofi Elf | Dérivés amino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. |
| JPH10504542A (ja) * | 1994-07-27 | 1998-05-06 | ジー．ディー．サール アンド カンパニー | 炎症処置用の置換チアゾール化合物 |
| AU689972B2 (en) | 1994-11-29 | 1998-04-09 | Hisamitsu Pharmaceutical Co., Inc. | Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof |
| RO119946B1 (ro) * | 1995-02-13 | 2005-06-30 | G.D. Searle & Co. | Derivaţi de izoxazol, utilizaţi pentru tratamentul inflamaţiilor |
| HUP9603433A3 (en) * | 1995-04-13 | 1998-04-28 | Taiho Pharmaceutical Co Ltd | 4-6-diaryl-pyrimidine-derivatives, process for producing them and pharmaceutical compositions containing them |
| JP4136024B2 (ja) | 1995-12-29 | 2008-08-20 | 富山化学工業株式会社 | ２−アミノチアゾ−ル誘導体またはその塩 |
| US5883105A (en) | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| JPH11263775A (ja) * | 1997-09-08 | 1999-09-28 | Sankyo Co Ltd | ヒドロキシアニリン誘導体 |
| US6262098B1 (en) * | 1998-08-07 | 2001-07-17 | Chiron Corporation | Estrogen receptor modulators |
| JP2002532729A (ja) * | 1998-12-23 | 2002-10-02 | グラクソ グループ リミテッド | 核内受容体のリガンドのアッセイ |
| US6201020B1 (en) * | 1998-12-31 | 2001-03-13 | Guilford Pharmaceuticals, Inc. | Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
| WO2000064876A1 (en) * | 1999-04-28 | 2000-11-02 | Aventis Pharma Deutschland Gmbh | Tri-aryl acid derivatives as ppar receptor ligands |
| DE19943636A1 (de) * | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| HUP0300382A3 (en) * | 2000-03-29 | 2006-11-28 | Cyclacel Ltd | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds |
| GB0030710D0 (en) * | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
-
2001
- 2001-08-13 AT AT01119473T patent/ATE381542T1/de not_active IP Right Cessation
- 2001-08-13 DE DE60131967T patent/DE60131967D1/de not_active Expired - Lifetime
- 2001-08-13 EP EP01119473A patent/EP1285914B1/de not_active Expired - Lifetime
-
2002
- 2002-07-01 US US10/185,721 patent/US7034046B2/en not_active Expired - Lifetime
- 2002-07-01 US US10/185,731 patent/US6974830B2/en not_active Expired - Lifetime
- 2002-08-13 EP EP02750473A patent/EP1423111A4/de not_active Withdrawn
- 2002-08-13 WO PCT/US2002/025437 patent/WO2003015771A1/en not_active Ceased
- 2002-08-13 EP EP02750472A patent/EP1423370A4/de not_active Withdrawn
- 2002-08-13 WO PCT/US2002/025436 patent/WO2003016288A1/en not_active Ceased
- 2002-08-13 US US10/217,141 patent/US7098336B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7098336B2 (en) | 2006-08-29 |
| EP1285914B1 (de) | 2007-12-19 |
| US20030187042A1 (en) | 2003-10-02 |
| EP1423370A4 (de) | 2007-04-18 |
| US7034046B2 (en) | 2006-04-25 |
| WO2003015771A1 (en) | 2003-02-27 |
| EP1285914A1 (de) | 2003-02-26 |
| US20030149087A1 (en) | 2003-08-07 |
| DE60131967D1 (de) | 2008-01-31 |
| EP1423111A4 (de) | 2007-04-18 |
| WO2003016288A1 (en) | 2003-02-27 |
| EP1423370A1 (de) | 2004-06-02 |
| EP1423111A1 (de) | 2004-06-02 |
| US20030130296A1 (en) | 2003-07-10 |
| US6974830B2 (en) | 2005-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE381542T1 (de) | Nr1h4-kern-rezeptor-bindende verbindungen | |
| ATE396186T1 (de) | Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5 | |
| EA200301216A1 (ru) | Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания | |
| DE60231341D1 (de) | Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten | |
| EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
| MEP45308A (en) | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | |
| CY1106969T1 (el) | Αναστολεις dpp-iv | |
| SE0303180D0 (sv) | Novel compounds | |
| SE0302232D0 (sv) | Novel Compounds | |
| ATE515505T1 (de) | Heterocyclische fxr-bindende verbindungen | |
| EA200601266A1 (ru) | Соединения триазола и их применение в качестве антагонистов метаботропного рецептора глутамата | |
| BRPI0000596B8 (pt) | composto piridona, processo de produção do composto, composição farmacêutica, e uso do dito composto | |
| PL1716152T3 (pl) | Skondensowane związki heterocykliczne i ich zastosowanie jako antagonistów receptora metabotropowego do leczenia zaburzeń żołądkowo-jelitowych | |
| DE60237528D1 (de) | Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative | |
| NO20063275L (no) | Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom | |
| EA200501595A1 (ru) | Азабициклические производные в качестве антагонистов мускаринового рецептора | |
| SE0301368D0 (sv) | Chemical compounds | |
| ATE377602T1 (de) | Morphinanderivate und ihre medizinische anwendung | |
| EP1398029A8 (de) | 3-substituierte Pyrazol-Derivate,die an den NR3B1 Rezeptor binden | |
| DE60221813D1 (de) | Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors | |
| EA200501594A1 (ru) | Замещенные производные азабициклогексана в качестве антагонистов мускаринового рецептора | |
| ATE386738T1 (de) | Flavaxat-derivate als muscarin-rezeptor antagonisten | |
| ATE454383T1 (de) | Neue verbindungen, deren verwendung und herstellung | |
| BRPI0519267A2 (pt) | derivado de quinolina, seu uso, produÇço e medicamento contendo o mesmo | |
| ATE398614T1 (de) | Triazolverbindungen und ihre therapeutische verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |